Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Limbach, Keith ^a,b   Aguiar, Joao ^a,b   Gowda, Kalpana ^a   Patterson, Noelle ^a,b   Abot, Esteban ^a,b   Sedegah, Martha ^a   Sacci, John ^c   Richie, Thomas ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MONTANIDE ISA 720; PLASMID DNA; RECOMBINANT PROTEIN PY 03011; RECOMBINANT PROTEIN PY 03424; RECOMBINANT PROTEIN PY 03661; RECOMBINANT PROTEIN PYCSP; UNCLASSIFIED DRUG; VIRUS VECTOR; DNA VACCINE; PARASITE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENTIATION; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; SPOROZOITE; VACCINIA VIRUS; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; MALARIA; PATHOGENICITY; RODENT DISEASE;

ANIMALS; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALARIA; MALARIA VACCINES; MICE; PLASMODIUM YOELII; RODENT DISEASES; VACCINES, DNA;

EID: 79952699626     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-65     Document Type: Article

References (39)

1. WHO, World Malaria Report 2009 Geneva: WHO Press, World Health Organization 2009
2. Spread and evolution of Plasmodium falciparum drug resistance. T Mita K Tanabe K Kita, Parasitol Int 2009 58 201 209 10.1016/j.parint.2009.04.004 19393762
3. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. SL Hoffman LM Goh TC Luke I Schneider TP Le DL Doolan J Sacci P de la Vega M Dowler C Paul D Gordon J Stoute L Church M Sedegah D Heppner W Ballou T Richie, J Infect Dis 2002 185 1155 1164 10.1086/339409 11930326 (Pubitemid 34297774)
4. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. A Vaughan R Wang S Kappe, Hum Vaccines 2010 6 107 113 10.4161/hv.6.1.9654
5. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. JA Stoute M Slaoui DG Heppner P Momin KE Kester P Desmons B Wellde N Garcon U Krzych M Marchand, N Engl J Med 1997 336 86 91 10.1056/ NEJM199701093360202 8988885 (Pubitemid 27020884)
6. The development of the RTS,S malaria vaccine candidate: challenges and lessons. WR Ballou, Parasite Immunol 2009 31 492 500 10.1111/j.1365-3024.2009. 01143.x 19691554
7. Protection from malaria sporozoite challenge correlates with frequency of TRAP-specific CD8+ T cells secreting IFN [abstract]. K Ewer K Collins G O'Hara C Duncan R Rowland A Reyes-Sandoval A Goodman I Poulton C Hutchings P Bird E Berrie A Nicosia S Colloca R Cortese L Siani A Lawrie S Gilbert A Hill, Malaria: New Approaches to Understanding Host-Parasite Interactions 2010 86
8. Phase 1/2a Clinical Trial on Safety, Tolerability, Immunogenicity and Efficacy of Prime Boost Regimen of DNA- and Adenovirus-vectored Malaria Vaccines Encoding Plasmodium falciparum Circumsporozoite Protein (CSP) and Apical Membrane Antigen (AMA1) in Malaria-Nave Adults [abstract]. I Chuang M Sedegah S Cicatelli M Spring C Tamminga J Bennett M Guerrero M Polhemus J Cummings E Angov J Bruder N Patterson K Limbach J Murphy E Bergmann-Leitner S Soisson C Diggs C Ockenhouse T Richie, Malaria: New Approaches to Understanding Host-Parasite Interactions 2010 83
9. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. BR Ogutu OJ Apollo D McKinney W Okoth J Siangla F Dubovsky K Tucker J Waitumbi C Diggs J Wittes E Malkin A Leach L Soisson J Milman L Otien C Holland M Polhemus S Remich C Ockenhouse J Cohen W Ballou S Martin E Angov V Stewart J Lyon D Heppner M Withers for the MSP-1 Malaria Vaccine Working Group, PLoS One 2009 4 4708 10.1371/journal.pone.0004708 19262754
10. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. I Sagara RD Ellis A Dicko MB Niambele B Kamate O Guindo O Kante M Niambele K Miura G Mullen M Pierce L Martin A Dolo D Diallo O Doumbo L Miller A Saul, Vaccine 2009 27 7292 7298 10.1016/j.vaccine.2009.10.087 19874925
11. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. B Genton I Betuela I Felger F Al-Yaman RF Anders A Saul L Rare M Baisor K Lorry G Brown D Pye D Irving T Smith H Beck M Alpers, J Infect Dis 2002 185 820 827 10.1086/339342 11920300 (Pubitemid 34226210)
12. Allele-specific efficacy of an AMA-1-based malaria subunit vaccine [abstract]. A Ouattara S Takala D Coulibaly N Amadou R Saye M Thera C Plowe O Doumbo, Am J Trop Med Hyg 2009 81 162
13. L-FABP is a critical host factor for successful malaria liver stage development. S Mikolajczak V Jacobs-Lorena D MacKellar N Camargo S Kappe, Inter J Parasitol 2007 37 483 489 10.1016/j.ijpara.2007.01.002 (Pubitemid 46399713)
14. Falstatin, a cysteine protease inhibitor of Plasmodium falciparum, facilitates erythrocyte invasion. KC Pandey N Singh S Arastu-Kapur M Bogyo PJ Rosenthal, PLoS Pathog 2006 2 1031 1041 10.1371/journal.ppat.0020117 (Pubitemid 44818623)
15. A proteomic view of the Plasmodium falciparum life cycle. L Florens M Washburn J Raine R Anthony M Grainger J Haynes J Moch N Muster J Sacci D Tabb A Witney D Wolters Y Wu M Gardner A Holder R Sinden J Yates D Carucci, Nature 2002 419 520 526 10.1038/nature01107 12368866
16. Discovery of gene function by expression profiling of the malaria parasite life cycle. D LeRoch Y Zhou P Blair M Grainger J Moch J Haynes P De La Vega A Holder S Batalov D Carucci Winzeler, Science 2003 301 1503 1508 10.1126/science.1087025 12893887 (Pubitemid 37128535)
17. Transcriptional analysis of in vivo Plasmodium yoelii liver stage gene expression. J Sacci J Ribeiro F Huang U Alam J Russell P Blair A Witney D Carucci A Azad J Aguiar, Mol Biochem Parasitol 2005 142 177 183 10.1016/j.molbiopara.2005.03.018 15876462 (Pubitemid 40835909)
18. High-throughput generation of P. falciparum functional molecules by recombinational cloning. J Aguiar J LaBaer P Blair V Shamailova M Koundinya J Russell F Huang W Mar R Anthony A Witney S Caruana L Brizuela J Sacci S Hoffman D Carucci, Genome Res 2004 14 2076 2082 10.1101/gr.2416604 15489329 (Pubitemid 39440189)
19. Discovering novel pre-erythrocytic antigens for malaria [abstract]. J Aguiar J Bolton J Wanga A Urquhart J Sacci K Limbach T Tsuboi C Ockenhouse T Richie, Am J Trop Med Hyg 2009 81 290
20. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. ME Perkus K Limbach E Paoletti, J Virol 1989 63 3829 3836 2547999 (Pubitemid 19205455)
21. Compact, synthetic, vaccinia virus early/late promoter for protein expression. S Chakrabarti JR Sisler B Moss, Biotechniques 1997 23 1094 1097 9421642 (Pubitemid 27523268)
22. Vaccinia virus as an expression vector. A Piccini ME Perkus E Paoletti, Methods Enzymol 1987 153 545 563 full-text 2828850
23. The wheat germ cell-free protein synthesis system: A key tool for novel malaria vaccine candidate discovery. T Tsuboi S Takeo TU Arumugam H Otsuki M Torii, Acta Trop 2010 114 171 176 10.1016/j.actatropica.2009.10.024 19913490
24. Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Y Charoenvit MF Leef LF Yuan M Sedegah RL Beaudoin, Infect Immun 1987 55 604 608 2434426 (Pubitemid 17021948)
25. Plasmodium falciparum infection and exoerythrocytic development in mice with chimeric human livers. JB Sacci Jr U Alam D Douglas J Lewis DL Tyrrell AF Azad N Kneteman, Int J Parasitol 2006 36 353 360 10.1016/j.ijpara.2005.10.014 16442544 (Pubitemid 43376117)
26. Direct gene transfer into mouse muscle in vivo. JA Wolff RW Malone P Williams W Chong G Acsadi A Jani P Felgner, Science 1990 247 1465 1468 10.1126/science.1690918 1690918
27. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. M Sedegah W Weiss JB Sacci Jr Y Charoenvit R Hedstrom K Gowda V Majam J Tine S Kumar P Hobart S Hoffman, J Immunol 2000 164 5905 5912 10820272 (Pubitemid 30389837)
28. Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. M Sedegah Y Charoenvit J Aguiar J Sacci R Hedstrom S Kumar A Belmonte D Lanar T Jones E Abot P Druilhe G Corradon J Epstein T Richie D Carucci S Hoffman, Genes Immun 2004 5 553 561 10.1038/sj.gene.6364125 15318164 (Pubitemid 39529972)
29. PlasmoDB database. http://PlasmoDB.org
30. Assessment and improvement of the Plasmodium yoelii yoelii genome annotation through comparative analysis. A Vaughan SY Chiu G Ramasamy L Li MJ Gardner AS Tarun S Kappe X Peng, Bioinformatics 2008 24 383 389 10.1093/bioinformatics/btn140 18586738
31. Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage. K Matuschewski J Ross S Brown K Kaiser V Nussenzweig S Kappe, J Biol Chem 2002 277 41948 41953 10.1074/jbc.M207315200 12177071 (Pubitemid 35257508)
32. Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins. K Kaiser K Matuschewski N Camargo J Ross SH Kappe, Mol Microbiol 2004 51 1221 1232 10.1046/j.1365-2958.2003.03909.x 14982620 (Pubitemid 38338888)
33. etramps, a new Plasmodium falciparum gene family coding for developmentally regulated and highly charged membrane proteins located at the parasite-host cell interface. T Spielmann DJ Fergusen HP Beck, Mol Biol Cell 2003 14 1529 1544 10.1091/mbc.E02-04-0240 12686607 (Pubitemid 36547420)
34. Interaction of an atypical Plasmodium falciparum ETRAMP with human apolipoproteins. M Vignali A McKinlay D LaCount R Chettier B Bell S Sahasrabudhe R Hughes S Fields, Malar J 2008 7 211 10.1186/1475-2875-7-211 18937849
35. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. AS Tarun RF Dumpit N Camargo M Labaied P Liu A Takagi R Wang S Kappe, J Infect Dis 2007 196 608 616 10.1086/519742 17624848 (Pubitemid 47206109)
36. Exoerythrocytic Plasmodium parasites secrete a cysteine protease inhibitor involved in sporozoite invasion and capable of blocking cell death of host hepatocytes. A Rennenberg C Lehmann A Heitmann T Witt G Hansen K Nagarajan C Deschermeier V Turk R Hilgenfeld V Heussler, PLoS Pathog 2010 6 1000825 10.1371/journal.ppat.1000825 20361051
37. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. DL Doolan M Sedegah RC Hedstrom P Hobart Y Charoenvit SL Hoffman, J Exp Med 1996 183 1739 1746 10.1084/jem.183.4.1739 8666931
38. Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. WR Weiss A Kumar G Jiang J Williams A Bostick S Conteh D Fryauff J Aguiar M Singh D O'Hagan J Ulmer T Richie, PLoS One 2007 2 1063 10.1371/journal.pone.0001063 17957247
39. Reduced immunogenicity of DNA vaccine plasmids in mixtures. M Sedegah Y Charoenvit L Minh M Belmonte VF Majam S Abot H Ganeshan S Kumar D Bacon A Stowers D Narum D Carucci W Rogers, Gene Ther 2004 11 448 456 10.1038/sj.gt.3302139 14973538 (Pubitemid 38313165)